Jury Still Out on Cardiovascular Safety of Testosterone ...Middle East

Medscape - News
A meta-analysis may provide some reassurance of the short-term cardiovascular safety of testosterone therapy for male hypogonadism until definitive 5-year TRAVERSE trial findings are available, expected in late 2022. Medscape Medical News

Hence then, the article about jury still out on cardiovascular safety of testosterone was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jury Still Out on Cardiovascular Safety of Testosterone )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News